Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis

Koichi Morishita, Nami Ito, Sayaka Koda, Megumi Maeda, Kotarosumitomo Nakayama, Kiyoshi Yoshida, Shinji Takamatsu, Makoto Yamada, Hidetoshi Eguchi, Yoshihiro Kamada, Eiji Miyoshi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.

Original languageEnglish
Pages (from-to)84-89
Number of pages6
JournalClinica Chimica Acta
Volume487
DOIs
Publication statusPublished - Dec 1 2018
Externally publishedYes

Fingerprint

Haptoglobins
Pancreatic Neoplasms
Immunosorbents
Phenotype
Assays
Enzyme-Linked Immunosorbent Assay
Enzymes
Serum
Glycosylation
Antibodies
Tumor Biomarkers
Lectins
ROC Curve
Area Under Curve
Polysaccharides
Neoplasms
Inflammation
Incidence

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. / Morishita, Koichi; Ito, Nami; Koda, Sayaka; Maeda, Megumi; Nakayama, Kotarosumitomo; Yoshida, Kiyoshi; Takamatsu, Shinji; Yamada, Makoto; Eguchi, Hidetoshi; Kamada, Yoshihiro; Miyoshi, Eiji.

In: Clinica Chimica Acta, Vol. 487, 01.12.2018, p. 84-89.

Research output: Contribution to journalArticle

Morishita, K, Ito, N, Koda, S, Maeda, M, Nakayama, K, Yoshida, K, Takamatsu, S, Yamada, M, Eguchi, H, Kamada, Y & Miyoshi, E 2018, 'Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis', Clinica Chimica Acta, vol. 487, pp. 84-89. https://doi.org/10.1016/j.cca.2018.09.001
Morishita, Koichi ; Ito, Nami ; Koda, Sayaka ; Maeda, Megumi ; Nakayama, Kotarosumitomo ; Yoshida, Kiyoshi ; Takamatsu, Shinji ; Yamada, Makoto ; Eguchi, Hidetoshi ; Kamada, Yoshihiro ; Miyoshi, Eiji. / Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. In: Clinica Chimica Acta. 2018 ; Vol. 487. pp. 84-89.
@article{13857fe431b64c65b6642c14ee1de711,
title = "Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis",
abstract = "Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.",
author = "Koichi Morishita and Nami Ito and Sayaka Koda and Megumi Maeda and Kotarosumitomo Nakayama and Kiyoshi Yoshida and Shinji Takamatsu and Makoto Yamada and Hidetoshi Eguchi and Yoshihiro Kamada and Eiji Miyoshi",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.cca.2018.09.001",
language = "English",
volume = "487",
pages = "84--89",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis

AU - Morishita, Koichi

AU - Ito, Nami

AU - Koda, Sayaka

AU - Maeda, Megumi

AU - Nakayama, Kotarosumitomo

AU - Yoshida, Kiyoshi

AU - Takamatsu, Shinji

AU - Yamada, Makoto

AU - Eguchi, Hidetoshi

AU - Kamada, Yoshihiro

AU - Miyoshi, Eiji

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.

AB - Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.

UR - http://www.scopus.com/inward/record.url?scp=85053807473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053807473&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2018.09.001

DO - 10.1016/j.cca.2018.09.001

M3 - Article

VL - 487

SP - 84

EP - 89

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -